×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Lung Cancer

Lidia Vitale
Lidia, who was diagnosed with stage 4 lung cancer in 2016, offers her advice for others who have received a cancer diagnosis.
 
GO2 Foundation
The aim is to explore the magnitude of the problem and give researchers and clinicians new insights to improve the quality of life for women lung cancer survivors.
Jessica Skarzynski
“These things cannot just shut down completely because these diseases don't exist in isolation,” says Dr. Paul Paik.
 
Jessica Skarzynski
For the treatment of patients with non-small cell lung cancer, the field has seen one approval after the other, but for one expert this is a sign that things are moving too fast to be applied in a "rational trial strategy". 
Jessica Skarzynski
In an interview with CURE®, Dr. Pail Paik of the Memorial Sloan Kettering Cancer Center discusses the FDA approval of Alunbrig for patients with ALK-positive metastatic non-small cell lung cancer.
Ashley Stringer
“I think until you've been put in a position that I'm in, we sometimes tend to take our lives and time that we have for granted.”
Danielle
“Everything is perspective. It's how you look at it.”
Ryan McDonald
According to data presented at the 2020 ASCO Virtual Scientific Program, increasing the dose of thoracic radiotherapy from the standard measurement of dosing improved survival in patients with limited-disease small cell lung cancer.
 
Ryan McDonald
According to lead study author Dr. Luis Paz-Ares, study findings confirm the use of the immunotherapy Imfinzi in combination with etoposide plus cisplatin or carboplatin (EP) as a new frontline standard of care for this patient population.
Kristie L. Kahl
The Food and Drug Administration approved the second biomarker-based indication for Keytruda to treat adult and pediatric patients with unresectable or metastatic TMB-H solid tumors across cancer types, including rare cancers.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×